Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease
Cardiovascular Drugs and Therapy · 2026-12 · 40 (6) · 2561-2562
DOI: 10.1007/s10557-026-07939-7 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 27.08.2026. Verfasst von Wei Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou Medical University, Wenzhou, 325035, China. 15657057690@139.com. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wenzhou Medical University, Wenzhou, 325035, China. 15657057690@139.com.
- Renji College, Wenzhou Medical University, Wenzhou, 325035, China. 15657057690@139.com.
- Wenzhou Medical University, Wenzhou, 325035, China.
Zitieren
APA
Chen, W., Wang, X., & Xiao, Y. (2026). Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease. Cardiovascular Drugs and Therapy, 40(6), 2561-2562. https://doi.org/10.1007/s10557-026-07939-7
Vancouver
Chen W, Wang X, Xiao Y. Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease. Cardiovascular Drugs and Therapy. 2026;40(6):2561-2562. doi:10.1007/s10557-026-07939-7
BibTeX
@article{Chen2026,
author = {Chen, Wei and Wang, Xiqin and Xiao, Yue},
title = {Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease},
journal = {Cardiovascular Drugs and Therapy},
year = {2026},
volume = {40},
number = {6},
pages = {2561--2562},
doi = {10.1007/s10557-026-07939-7}
}
EUVIMED